/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | LMMYExousia Bio, Inc. |
|---|---|
| Last close | no stored close |
| Change % | no stored close |
| Market cap | no stored close |
| P/E | no stored close |
| Revenue | no revenue filed |
| Rev growth (YoY) | no revenue filed |
| Net income | $51395⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-05-31 Filing10-K · 0001683168-25-007621 · filed 2025-10-17 Open the filing on EDGAR →Open the XBRL payload →CiteExousia Bio, Inc. (LMMY), us-gaap:NetIncomeLoss: 51,395 USD, fiscal year ended 2025-05-31. Form 10-K, accession 0001683168-25-007621, filed 2025-10-17. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001939937/us-gaap/NetIncomeLoss.json |
| Net margin | not filed |
| EPS (diluted) | $0.00⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-05-31 Filing10-K · 0001683168-25-007621 · filed 2025-10-17 Open the filing on EDGAR →Open the XBRL payload →CiteExousia Bio, Inc. (LMMY), us-gaap:EarningsPerShareDiluted: 0.00 USD per share, fiscal year ended 2025-05-31. Form 10-K, accession 0001683168-25-007621, filed 2025-10-17. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001939937/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | 2FY to 2025-05-31 |
| Altman Z-ScoreUNVALIDATED | inputs not filed |
| Beneish M-ScoreUNVALIDATED | inputs not filed |
| Next earnings | — |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.